Rani Therapeutics (US:RANI) Investorideas.com·2025-10-17 15:40Core Insights - Rani Therapeutics has entered into a significant Collaboration and License Agreement with Chugai Pharmaceutical, valued at up to $1.085 billion, focusing on the development of an oral product utilizing Rani's RaniPill technology and Chugai's antibody for rare diseases [4][5][6] Financial Details - The initial agreement includes a $10 million upfront payment, potential for up to $75 million in technology transfer and development milestones, and up to $100 million in sales milestones, along with single-digit royalties on product sales [5][7] - Rani also completed an oversubscribed private placement financing of $60.3 million, led by Samsara BioCapital and other notable investors [5][8] Strategic Importance - The partnership aims to address unmet medical needs in rare and immunologic diseases by providing oral therapies, which could enhance patient adherence and quality of life compared to traditional injection methods [6][7] - CEO Talat Imran emphasized the collaboration as a convergence of Rani's innovative technology and Chugai's expertise, targeting multiple disease areas with high unmet needs [6][7]